Botulism Market

SKU: DMMD1705 | Last Updated On: Sep 25 2022 | Available Formats

> Botulism Market Expected to reach a high CAGR of 7.5% By 2029

Botulism Market is segmented by By Toxin type (Type A, Type B, Type C, Type D, Type E, Type, F, Type G, Type H), By Botulism Type (Foodborne Botulism, Wound Botulism, Infant Botulism, Others (Adult intestinal colonization, Iatrogenic botulism)), By Treatment Type (Antitoxin, Antibiotics, Breathing assistance, Cathartics, Others), By End User (Hospital Pharmacies, Clinics, Retail pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

[150 Pages Report] The Botulism Market is expected to grow at a CAGR of 7.5% during the forecasting period (2022-2029).

Botulism Market - Strategic Insights



Market CAGR


Segments Covered

By Toxin type, By Botulism Type, By Treatment Type, By End User and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Botulism is a severe condition of food poisoning caused when one consumes toxin-containing food. Clostridium botulinum is an anaerobic, rod-shaped the spore-forming bacterium which is capable of growing in food-producing toxins, and this toxin has a degree of neurotoxicity. The currently available botulinum antitoxin is a horse serum-derived product that has side effects of serum sickness, anaphylaxis, and possible life-long sensitization to equine proteins. Clinical diagnosis of botulism is most effectively confirmed by identifying botulinal toxin in the blood, feces, or vomitus of the patient.

Botulism Market Dynamics

Botulism market is primarily driven by the increase in food poisoning, availability of efficient botulism solutions, and favorable reimbursement policies.

For example, on 2nd June 2016, Revance Therapeutics Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications announced the expansion of botulinum toxin-related assets by acquiring a portfolio of botulinum toxin-related patents and patent applications from Botulinum Toxin Research Associates Inc.

However, high-cost investments required for the treatment, strict government regulations, the wrong diagnosis are expected to restrain the growth of the market for botulism. For instance, an Arizona company got shut down after four people got paralyzed when injected with botulin toxins that were not approved for human use.

In November 2018, Food and Drug Administration (FDA) gave a public warning to Gonzalez and Nietos LLC which included serious violations including cockroaches in the facility and packaging issues that will favor the growth of Clostridium botulinum that produces the toxin causing botulism poisoning.

Botulism Market Segmentation Analysis

Infant botulism is expected to have the highest share in the botulism type segment of the global botulism market.

According to the National Botulism Surveillance Summary 2016, 205 botulism cases were reported to Center for Diseases Control and Prevention (CDC) in 2016 with confirmation, out of which 150 (73%) were infant botulism cases, 29 (14%) were foodborne botulism cases, 24 (12%) were wound botulism cases, and 3 (1%) were of unknown etiology.

Type A botulinum is expected to have the highest share in the toxin type segment of the global botulism market.

According to CDC, in 2016, in the U.S.,  102 botulism cases were caused by type A toxin, 92 botulism cases caused by type B toxin and 11 botulism cases due to the other toxins (type Ab, Bf, Ba, etc.) including type E and type F toxins.

Geographical Analysis

North America is expected to hold the highest share in the botulism market owing to the increasing clostridium botulinum infections in the region.

According to the CDC, Alaska is noted to have the highest foodborne botulism incidence than any other state in the country. It is reported from 1950 to 2017 that more than 350 people in Alaska have botulism, out of which 24 people have died. People in Alaska were infected with botulism by eating traditional Alaska native foods such as fermented fish heads, egg heads, beaver tails, seal flipper, etc

Europe is expected to have a significant share in the botulism market owing to the increasing awareness of different types of bacteria and strict government regulations interference to ensure better safety of the people in the region.

For instance, on 31st January 2019, Grupo Dia recalled a batch of canned sardines in olive oil in Spain and Portugal because of the risk of botulinum toxin that can cause botulism.

Competitive Analysis

The strategies used by key players include mergers and acquisitions, partnerships, and product launches to expand and stand out as strong competitors in the market. New product launches along with an increased focus on R&D are other ways the leading players improve their market presence. The key players in the botulism market are

Allergan Inc., Emergent BioSolutions Inc., Galderma S. A, Ipsen Technologies Pvt. Ltd, Valeant Pharmaceuticals Inc., AlphaVax Inc., Merz Pharma GmbH, Revance Therapeutics Inc., Microbiotix Inc., and XOMA Corporation.

On 2nd February 2019, Korean-based Daewoong Pharmaceutical’s Jeuveau, a botulinum toxin receives U.S. FDA approval. The product will be sold by Evolvus Inc., a local partner specialized in selling products for aesthetics in the U.S.

On 16th February 2019, Smoked Alaska Seafoods Inc. of Wasilla recalled all jars and cans of Smoked Silver Salmon owing to the high probability of getting contaminated with Clostridium botulinum, a bacterium that can cause life-threatening illness or death.

Why Purchase the Report?

  • Visualize the composition of the global botulism market across each indication, in terms of toxin type, botulism type, treatment, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in global botulism market by analyzing trends and co-development deals.
  • Excel a data sheet with thousands of data points of the global botulism market-level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Trending Topics

Botulinum Toxin Market

Metabolism Drugs Market


What is the Botulism Market growth?

The market is growing at a CAGR of 7.5%

What is Botulism Market size in 2021

The Botulism Market size was valued at USD YY million in 2021

Who are the key players in Botulism Market?

Allergan Inc., Emergent BioSolutions Inc., Galderma S. A, Ipsen Technologies Pvt. Ltd, Valeant Pharmaceuticals Inc.

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!